bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 15 citations · 47 references
Life SciencesBiochemistryInfectious DiseasesMetabolomicsMolecular VirologyProteomicsMolecular Mechanisms Of ToxicityOxidative Damage To BiomoleculesProtein OxidationProteomic ProfilingReactive MetabolitesReactive Oxygen SpeciesFunctional Analysis Of Protein DomainsOxidative Damage To ProteinsProtein Oxidation In DiseaseReactive Oxygen Species GenerationReactive Oxygen Species InjurySars-cov-2 InfectionToxic MetabolitesViral Therapeutic Targets
SUMMARY The global pandemic of COVID-19 disease caused by infection with the SARS-CoV-2 coronavirus, has produced an urgent requirement and search for improved treatments whilst effective vaccines are developed. A strategy for improved drug therapy is to increase levels of endogenous reactive metabolites for selective toxicity to SARS-CoV-2 by preferential damage to the viral proteome. Key reactive metabolites producing major quantitative damage to the proteome in physiological systems are: reactive oxygen species (ROS) and the reactive glycating agent methylglyoxal (MG); cysteine residues and arginine residues are their most susceptible targets, respectively. From sequenced-based prediction of the SARS-CoV-2 proteome, we found 0.8-fold enrichment or depletion of cysteine residues in functional domains of the viral proteome; whereas there was a 4.6-fold enrichment of arginine residues, suggesting SARS-CoV-2 is resistant to oxidative agents and sensitive to MG. For arginine residues of the SARS-CoV-2 predicted to be in functional domains, we examined which are activated towards modification by MG – residues with predicted or expected low pK a by neighbouring group in interactions. We found 25 such arginine residues, including 2 in the spike protein and 10 in the nucleoprotein. These sites were partially conserved in related coronaviridae : SARS-COV and MERS. Finally, we identified drugs which increase cellular MG concentration to virucidal levels: antitumor drugs with historical antiviral activity, doxorubicin and paclitaxel. Our findings provide evidence of potential vulnerability of SARS-CoV-2 to inactivation by MG and a scientific rationale for repurposing of doxorubicin and paclitaxel for treatment of COVID-19 disease, providing efficacy and adequate therapeutic index may be established.
47
SWISS-MODEL: homology modelling of protein structures and complexes
Andrew Waterhouse, Martino Bertoni, Stefan Bienert et al. · Nucleic Acids Research · 2018 · 13.6K citations · Full text
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett et al. · Science · 2020 · 9.8K citations · Full text
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon, Gwendolyn Μ. Jang, Mehdi Bouhaddou et al. · Nature · 2020 · 4.9K citations · Full text
The EMBL-EBI search and sequence analysis tools APIs in 2019
Fábio Madeira, Young Mi Park, Joon Lee et al. · Nucleic Acids Research · 2019 · 4.7K citations · Full text